What clinical or logistical factors influence your choice of anti-CD38 antibody in first-line treatment of multiple myeloma?

I generally use daratumumab, because subcutaneous is more convenient for patients, and we go to once-a-month dosing much quicker with daratumumab compared to isatuximab. Once isatuximab subcutaneous is available, this advantage of daratumumab may be lost, but given comfort and familiarity with darat...

I agree with Dr. @Dr. First Last, Dara has been used longer and is easier to administer due to the subq formulation. Isatuximab is somewhat different than Dara and is an IV infusion. However, I have used both in 1st line and find both to be very effective when used in front-line quad induction.

In ...

Off-trial, we tend to offer anti-CD38 to all newly diagnosed patients due to the ease of administration, particularly in renal failure. Most of the time we use daratumumab, unless patients are receiving another in-clinic medication, e.g. carfilzomib. I assume isatuximab will proceed with the develop...

Of note, in addition to the MAIA and CEPHEUS studies, there are several similar phase 3 studies that used isatuximab, the other available anti-CD38 monoclonal antibody for MM. The IMROZ study (Facon et al., PMID 38832972) compared IsaVRd to VRd in transplant-ineligible MM and found improved response...